Abstract: The invention relates to a method for producing biperiden by reacting exo-1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone with a phenylmagnesium compound. According to the invention, exo-1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone can be obtained by reacting the exo-ether of enol silylene of formula (IV) with a compound of N-methylenepiperidinium.

Abstract: A process for reducing the content of ethyl 3-dimethylamino-2-phenylpropionate in a solution, contaminated therewith, of ethyl 2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylate in a water-immiscible solvent, which comprises adding from 0.5 to 2.0 equivalents of a carboxylic acid per mole of ethyl 2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylate to this solution, and stirring this mixture at a temperature of from 50° C. to 100° C., is described.

Abstract: The invention relates to a method for the production of biperiden by reacting an exo/endo mixture of 1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone with a phenyl magnesium compound to form an isomer mixture of 1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-piperidino-1-propanol, whereby biperiden is obtained therefrom by conversion of said mixture into corresponding hydrochloride, isolation of said hydrochloride, reconversion to the free base and crystallization of said biperiden.

Abstract: The invention relates to a method for the production of biperiden by reacting an exo/endo mixture of 1-(bicyclo[2.2.1.]hept-5-en-2-yl) 3-piperidino-1-propanone with a phenyl magnesium compound, wherein the exo/endo ratio of 1-(bicylo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone is at least 4.5:1.

Abstract: The invention relates to a method for producing biperiden by reacting exo-1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone with a phenylmagnesium compound. According to the invention, exo-1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone can be obtained by reacting the exo-ether of enol silylene of formula (IV) with a compound of N-methylenepiperidinium.

Abstract: The invention relates to a method for the production of biperiden by reacting an exo/endo mixture of 1-(bicyclo[2.2.1.]hept-5-en-2-yl) 3-piperidino-1-propanone with a phenyl magnesium compound, wherein the exo/endo ratio of 1-(bicylo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone is at least 4.5:1.

Abstract: The invention relates to a method for the production of biperiden by reacting an exo/endo mixture of 1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone with a phenyl magnesium compound to form an isomer mixture of 1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-piperidino-1-propanol, whereby biperiden is obtained therefrom by conversion of said mixture into corresponding hydrochloride, isolation of said hydrochloride, reconversion to the free base and crystallization of said biperiden.

Abstract: A process for preparing ethyl atropate by reacting ethyl phenylacetate with paraformaldehyde in the presence of a base is described and entails employing as ethyl phenylacetate a product which contains not more than 0.03% of the corresponding methyl phenylacetate, and carrying out the reaction in N-methyl-pyrrolidone or N,N-dimethylformamide.

Abstract: A process for preparing doxazosin mesylate in modification A which comprises dissolving doxazosin with methanesulfonic acid in methanol or a mixture of an aprotic, polar organic solvent and methanol, removing any turbidity from the resulting solution, and stirring the resulting clear solution until no further precipitate separates out, removing, washing with methanol, heating the precipitate in the moist state in ethanol and, after cooling, isolating the resulting product is described.

Abstract: The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.

Abstract: Drugs comprising modification D of doxazosin mesylate are described. They are suitable for treating high blood pressure.

Abstract: The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.

Abstract: The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.

Abstract: Compounds of the formula where R1, R2, R3 and R4 have the meaning stated in the description, and a process for preparing them are described. The compounds are suitable as starting material for synthesizing substances which are active against tumors.

Abstract: Compounds of the formula ##STR1## where R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meaning stated in the description, and a process for preparing them are described. The compounds are suitable as starting material for synthesizing substances which are active against tumors.

Abstract: The compound Me.sub.2 Val--Val--MeVal--Pro--Pro--NHBzl.multidot.HCl is described. It is prepared from Z--Val--Val--MeVal--Pro--OR.sup.1 where Z and R.sup.1 have the meanings stated in the description. The compound shows antineoplastic activity.

Abstract: Alkyl .gamma.-halotiglates of the general formula I ##STR1## where X is Cl or Br and R.sup.2 is alkyl of 1 to 3 carbon atoms, having a high E isomer content, are prepared by a process in which(a) the corresponding 2-methyl-but-3-enoate of the general formula II ##STR2## is reacted with chlorine or bromine in the absence of a solvent and (b) the resulting 2-methyl-3,4-dihalobutyrate of the general formula III ##STR3## is dehydrohalogenated by reaction with a solution of an alkali metal hydroxide in an alcohol R.sup.2 OH, where R.sup.2 has the stated meaning, or in a mixture of water and an alcohol R.sup.2 OH, and the products are further processed to give O,O-dialkyl-.gamma.-phosphonotiglates of the general formula IV ##STR4## where R.sup.1 is alkyl of 1 to 4 carbon atoms and R.sup.2 is alkyl of 1 to 3 carbon atoms, preferably ethyl, by reaction with a trialkyl phosphite and thermal isomerization. The process gives C.sub.

Abstract: Novel 6-(acylaminaryl)-3(2H)-pyridazinones of the formula ##STR1## where R.sup.1, R.sup.2, R.sup.3, R.sup.4, A and B have the meanings given in the description, and their preparation are described.The compounds have thrombocyte aggregation-inhibiting activity.

Abstract: (Z)-2-(2-arylethenyl)arylcarboxylic acids of the general formula I ##STR1## where A is a group for completing an aromatic ring system and Ar is an aromatic radical, are prepared by reacting a 2-formylarylcarboxylic acid of the general formula II ##STR2## with an (arylmethyl)phosphonium salt of the general formula III ##STR3## where R.sup.1, R.sup.2 and R.sup.3 are each organic radicals and X is halogen, in the presence of a base at from (-20.degree.) to +30.degree. C. by carrying out the reaction in the presence of a C.sub.1 -C.sub.5 -alkanol and/or a C.sub.2 -C.sub.4 -alkanediol.

Abstract: Novel 6-(acylaminoaryl)-3(2H)-pyridazinones of the formula ##STR1## where R.sup.1, R.sup.2, R.sup.3, R.sup.4, A and B have the meanings given in the description, and their preparation are described.[.and inhibiting thrombocyte aggregation and gastric secretion.]..The compounds are useful for treating disorders .Iadd.and inhibiting thrombocyte aggregation and gastric secretion.Iaddend..